HLB Appoints Kim Dong-gun as CEO of U.S. Subsidiary Elevar Therapeutics
HLB has appointed Kim Dong-gun, head of HLB US, as chief executive officer of its U.S. subsidiary Elevar Therapeutics.
As CEO of Elevar Therapeutics, he will lead FDA regulatory strategies and commercialization efforts. He will also continue to serve as head of HLB US and chief executive officer of Immunomic Therapeutics, overseeing HLB’s U.S. operations.
IT Times: https://www.ittimes.com/news/articleView.html?idxno=82995
HLB Appoints Kim Dong-gun as CEO of U.S. Subsidiary Elevar Therapeutics - IT타임스
HLB has appointed Kim Dong-gun, head of HLB US, as chief executive officer of its U.S. subsidiary Elevar Therapeutics, the company said on Jan. 29.The leadership change follows the completion of Ne...
www.ittimes.com